<DOC>
	<DOCNO>NCT01184560</DOCNO>
	<brief_summary>The purpose study , conduct academic Pilot research purpose , clear permit . orlistat sibutramine merge additional effect BMI group , attribute great combined effect analyze . - Study phase : Investigator-initiated clinical study ( Pilot study ) - Method blinding : Double-blind - Control : Placebo-controlled - Assignment method : Randomization ( Sibutramine monotherapy group : Orlistat Sibutramine combination group = 1 : 1 ) - Studied disease : Obesity - Study population : Subjects eligible inclusion/exclusion criterion - Dosing period : Total 18 week Run-in period ( 2 week ) , dose period ( 12 week ) post-dosing observation period ( 4 week )</brief_summary>
	<brief_title>Assess Additional Weight Loss Effect Orlistat Used Combination With Sibutramine</brief_title>
	<detailed_description>After screen period , patient eligible inclusion/exclusion criterion would administer Sibutramine placebo Orlistat placebo 2 week run-in period , Subsequently , subject randomize 2 group Sibutramine monotherapy group Orlistat Sibutramine combination group . Sibutramine monotherapy group would receive Sibutramine 10mg daily Orlistat placebo three time daily 12 week ; Orlistat Sibutramine combination group would receive Sibutramine 10mg daily Orlistat 120mg three time daily 12 week . After complete dose period , occurrence adverse event would check 4 week study would complete . Body weight , abdominal CT ( Computed Tomography ) ( visceral fat examination ) , body fat analysis , etc . would measure study initiation 14 week treatment , comparatively analyze . A two sample t-test conduct inter-group comparison pair t-rest conduct comparison baseline 14 week study initiation .</detailed_description>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Orlistat</mesh_term>
	<mesh_term>Sibutramine</mesh_term>
	<criteria>MAO 1 . A patient give one 's voluntary write consent participate clinical study 2 . Aged ≥ 18 &lt; 50 year old 3 . An obese patient body mass index ( BMI ) ≥ 27 kg/m2 4 . In case woman , premenopausal woman 1 . A patient weight change ≥ 5 % past 3 month 2 . A patient receive MAO ( monoamine oxldase ) inhibitor within 1 month screen 3 . A patient active acute chronic disease participation study 4 . A patient malignancy history within past 5 year 5 . A patient diagnose secondary obesity ( Cushing 's syndrome , thyroid disease , etc . ) 6 . A patient significant cardiovascular disease ( coronary vascular disease , congestive heart failure , peripheral arterial obstructive disease , arrhythmia , cerebrovascular disease , etc . ) , poorly control hypertension define JNC ( Joint National Committee ) 7 guideline , diabetes , severe hepatic/renal disease CNS ( Central Nervous System ) disease , drug abuse , psychiatric disorder , positive prostatic hyperplasia concurrent urinary retention glaucoma within past 1 year accord medical record 7 . A patient fall following screen test result Hemoglobin &lt; 10g/L platelet &lt; 100* 103/μL Total bilirubin &gt; 2.0mg/dL Serum GOT ( Glutamate oxaloacetate transaminase ) GPT ( glutamic pyruvate transaminase ) &gt; 120 IU/L Serum creatinine &gt; 1.4mg/dL Serum uric acid &gt; 10mg/dL Thyroid stimulate hormone &lt; 0.1μIU/mL &gt; 6.5 μIU/mL 8 . A patient clear unexplained abnormal finding chest Xray , urinalysis , electrocardiogram 9 . A pregnant woman breastfeed mother 10 . A patient participate another clinical study study 11 . Other patient legally mentally appropriate participate clinical study , judgment investigator 12 . A person participate clinical study within past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>obesity</keyword>
</DOC>